Market Study on mRNA Vaccines & Therapeutics 2017: An Industry Analysis of Technologies, Pipelines, Stakeholders and Deals
For a long time, messenger RNA (mRNA) was thought to be a poor choice for a therapeutic agent given its relatively short half-life and its immunogenicity. But mRNA is rather versatile and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity....
View full press release